{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:02:12Z","timestamp":1753887732552,"version":"3.41.2"},"reference-count":4,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.1542\/peds.2020-0867a","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T12:25:19Z","timestamp":1590755119000},"source":"Crossref","is-referenced-by-count":1,"title":["CYP2C19 Phenotype and Risk of Proton Pump Inhibitor\u2013Associated Infections"],"prefix":"10.1542","volume":"145","author":[{"given":"Kunal","family":"Gupta","sequence":"first","affiliation":[{"name":"Neonatologist, Hennepin Healthcare System, Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"issue":"6","key":"2021121014044775100_B1","doi-asserted-by":"crossref","first-page":"e20190857","DOI":"10.1542\/peds.2019-0857","article-title":"CYP2C19 phenotype and risk of proton pump inhibitor-associated infections","volume":"144","author":"Bernal","year":"2019","journal-title":"Pediatrics"},{"issue":"2","key":"2021121014044775100_B2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40272-013-0012-x","article-title":"Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics","volume":"15","author":"Ward","year":"2013","journal-title":"Paediatr Drugs"},{"key":"2021121014044775100_B3","first-page":"S43","article-title":"New-generation proton pump inhibitors: overcoming the limitations of early-generation agents","volume":"13","author":"Robinson","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"2021121014044775100_B4","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/apt.12492","article-title":"Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole","volume":"38","author":"Sahara","year":"2013","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-0867A\/1079308\/peds_20200867a.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-0867A\/1079308\/peds_20200867a.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T03:45:53Z","timestamp":1639194353000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/145\/6\/e20200867A\/76935\/CYP2C19-Phenotype-and-Risk-of-Proton-Pump"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":4,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,1]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2020-0867a","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2020,6,1]]},"article-number":"e20200867A"}}